OBJECTIVES: To analyse the effectivity and safety of tacalcitol in real daily conditions. METHODS: An epidemiological, observational, prospective and multicenter study of a cohort of patients with mild to moderate Psoriasis vulgaris has been performed. Treatment with tacalcitol ointment (4 mg/g). was prescribed. Anthropometric and demographic characteristics of patients were recorded in addition to percentage of affected area and previous and current treatments. A lesion was selected as target for evaluation, of symptoms (erythema, desquamation and thickness) by a scale from 0 (absent) to 4 ( maximum intensity of symptom). At follow-up (30 and 60 days) symptomatology and appearance of adverse events were evaluated. Psoriasis Area Severity Index (PASI) was calculated. RESULTS: Eight hundred twenty one patients with mild to moderate Psoriasis vulgaris, (45,67% were men and 45,33% were women, mean age 43,59± 15,48 years) were included. After 2 months of treatment, patients showed a decrease of mean percentage of affected area of 7,83± 12,3 (from 15,97% ± 16,02% to 8,14±10,59). PASI decreased from 10,11±7,89 to 3,00±3,79 (p <0.01). Percentage of patients without symptoms increased up to 85,44% for erythema, 93,11% for desquamation and 96,16% for thickness. Six adverse events were reported (1% of sample). Seventy-eight percent of investigators and 80% of patients evaluated effectivity of treatment as satisfactory. CONCLUSIONS: Tacalcitol was effective in symptomatic treatment of psoriasis. Treatment achieved improvement on affected area and intensity of symptoms as well. Excellent tolerability of tacalcitol was corroborated by the low rate of adverse events reported.